Description

Rezonativ (anti-d human immunoglobulin) solution for injections 625 IU/ml. 2 ml. ampoule №1

Ingredients

Rezonativ contains anti-d human immunoglobulin as the active ingredient.

Dosage

The recommended dosage of Rezonativ is determined by a healthcare professional based on the patient’s condition. It is typically administered via injection.

Indications

Rezonativ is indicated for the prevention of hemolytic disease of the newborn (HDN) in Rh D-negative pregnant women.

Contraindications

Do not use Rezonativ if you have a history of severe allergic reactions to human immunoglobulins.

Directions

Follow the instructions provided by your healthcare provider for the proper administration of Rezonativ. It is usually given as an intramuscular injection.

Scientific Evidence

Studies have shown that anti-D immunoglobulin therapy, such as Rezonativ, is highly effective in preventing the development of HDN in Rh D-negative pregnant women. Research published in the Journal of Perinatal Medicine demonstrated a significant reduction in the incidence of HDN with the use of anti-D immunoglobulins.

Additional Information

It is important to note that Rezonativ should only be administered under the supervision of a healthcare professional. Before using this medication, inform your doctor about any existing medical conditions or medications you are taking.

Clinical trials have also shown that Rezonativ has a good safety profile with minimal side effects, making it a reliable option for the prevention of HDN.